Structure Therapeutics has a strong cash position with a runway of 18-20 quarters, but the drug's potential is not fully ...
There are more than 300 GLP-1Rs in an active stage of development, from industry giants and potential market disrupters.
Jimmy Carter dies at 100. 179 people were killed in South Korea in a deadliest place crash of 2024. Trump praises H-1B visas.
GLP-1 is the same gut receptor targeted by Novo Nordisk’s Ozempic and Wegovy. Eli Lilly’s Mounjaro and Zepbound also hit that receptor as well as another one called GIP. All of these drugs are ...
Her light blonde hair was worn in a sleek bun, allowing her to show off her impeccable bone structure ... with the popular weight-loss drug Ozempic.'I took, like, a little bit when it first ...
We recently compiled a list of the 12 Best Weight Loss Stocks to Buy According to Hedge Funds. In this article, we are going ...
Investors appeared disappointed by CagriSema’s Phase III readout, which showed weight loss that fell short of Novo Nordisk’s ...
Merck & Co. snagged a potential drug in the burgeoning market for obesity medications in a deal worth as much as $2 billion.
MERCK snagged a potential drug in the burgeoning market for obesity medications in a deal worth as much as US$2 billion. Read ...
It would have been impossible to predict then that she'd become instrumental in the development of the popular class of injectable diabetes and weight loss drugs like Ozempic and Wegovy that have ...
The most recent, Ozempic and Mounjaro ... reflects a potential 173.41% increase from the current price of $6.92. Structure Therapeutics Inc. (NASDAQ:GPCR) is a clinical-stage biopharmaceutical ...
This year saw several advancements across medicine, space technology, and AI that extend our knowledge in consequential ways.